Latest Market Challenges News

Mineral Resources Limited posted a substantial $809 million loss for the half-year ending December 2024, driven by lower revenues and significant impairment charges, notably at its Bald Hill lithium project. The company also announced no interim dividend as it focuses on liquidity and operational transitions.

ARB Corporation Limited has announced a fully franked ordinary dividend of AUD 0.34 per share for the half-year ending December 2024, alongside Dividend Reinvestment and Bonus Security Plans.

SG Fleet Group reported robust first-half 2025 results, driven by strong delivery volumes and revenue growth across Australia, New Zealand, and the UK, despite ongoing pressures in the used vehicle market.

Environmental Clean Technologies Limited (ECT) has raised $750,000 through a two-tranche placement to fund its innovative COLDry Fertiliser Project and pursue strategic acquisitions, alongside key board changes.

SEEK Limited reported robust half-year results for FY2025, with gains in placement share and yield offsetting volume declines, alongside a significant rise in free cash flow and an increased interim dividend.

Ramelius Resources will release its half-year financial results for FY25 on 21 February, accompanied by a detailed investor conference call.

Big River Industries reported a 3.3% revenue decline and a 26% drop in EBITDA for 1H FY25, reflecting ongoing residential market challenges. Despite this, the company is investing in growth and operational efficiencies, maintaining a cautiously optimistic outlook for FY26 and beyond.

Big River Industries reports a 3.3% revenue decline in 1H FY25 but shows signs of operational resilience and strategic progress amid challenging market conditions.

Reliance Worldwide Corporation posts a robust 14.8% sales increase and a 31.8% jump in net profit for H1 FY25, driven by the Holman acquisition and solid cost efficiencies.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Simonds Group reported a resilient first half of FY25 with EBITDA growth despite market softness and announced a strategic acquisition to strengthen its market position.

The Star Entertainment Group has received a $650 million debt refinancing proposal from Oaktree Capital Management, offering a potential boost to its liquidity but shadowed by significant conditions and uncertainty.